UP!

DGX $111.7   View long term graphs

Quest Diagnostics
Type
Public
Traded as NYSE: DGX
S&P 500 Component
Industry Health care
Founded New York City, United States (1967)
Founder Paul Brown
Headquarters Madison, New Jersey, United States
Area served
United States, Brazil, Mexico, United Kingdom, India
Key people
Steve Rusckowski (CEO)
Revenue IncreaseUS$7.5 Billion (2015)
Operating income
IncreaseUS$1.4 Billion (2015)
Net income
IncreaseUS$0.7 Billion(2015)
Total assets IncreaseUS$10.0 Billion(2015)
Total equity IncreaseUS$4.7 Billion (2015)
Number of employees
44,000 (2015)
Website questdiagnostics.com

Quest Diagnostics Incorporated is a Fortune 500 American company providing clinical laboratory services with headquarters in Secaucus, New Jersey. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. The company has approximately 44,000 employees, generates more than $7 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders.

Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state’s Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.

News

Quest Diagnostics Incorporated 2.3% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-01-28 Future report Set alerts
Q3 2020 2020-10-20 Future report Set alerts
Q2 2020 2020-07-23 1.42 1.36
Q1 2020 2020-04-22 0.94 0.73
Q4 2019 2020-01-30 1.67 1.86
Q3 2019 2019-10-22 1.76 1.56
Q2 2019 2019-07-23 1.73 1.51
Q1 2019 2019-04-23 1.40 1.20
Q4 2018 2019-02-14 1.36 0.92
Q3 2018 2018-10-23 1.68 1.53

Ratings

2016-06-24 Downgrade Jyske Bank Neutral to Sell
2016-06-07 Reiterated Rating Morgan Stanley Sell
2016-06-03 Reiterated Rating Mizuho Buy $84.00
2016-05-24 Reiterated Rating Credit Suisse Hold
2016-05-24 Reiterated Rating Credit Suisse Group AG Hold
2016-05-22 Reiterated Rating KeyBanc Hold
2016-05-22 Reiterated Rating KeyCorp Hold
2016-05-16 Reiterated Rating Robert W. Baird Hold
2016-05-02 Reiterated Rating Robert W. Baird Hold
2016-04-23 Reiterated Rating Canaccord Genuity Buy
2016-04-22 Boost Price Target Barclays Equal Weight $72.00 to $75.00
2016-04-22 Boost Price Target RBC Capital Sector Perform $70.00 to $76.00
2016-04-22 Boost Price Target Barclays PLC Equal Weight $72.00 to $75.00
2016-04-22 Boost Price Target Royal Bank Of Canada Sector Perform $70.00 to $76.00
2016-04-21 Reiterated Rating Mizuho Buy $75.00 to $84.00
2016-03-23 Boost Price Target Goldman Sachs $71.00
2016-03-23 Boost Price Target Goldman Sachs Group Inc. $71.00
2016-03-15 Initiated Coverage Credit Suisse Neutral $72.00
2016-03-01 Upgrade Mizuho Neutral to Buy $68.00 to $75.00
2016-01-29 Reiterated Rating William Blair Hold
2016-01-29 Lower Price Target Barclays Equal Weight $74.00 to $72.00
2016-01-29 Lower Price Target RBC Capital Sector Perform $73.00 to $70.00
2016-01-07 Boost Price Target Barclays Equal Weight $72.00 to $74.00
2015-11-13 Boost Price Target Canaccord Genuity Buy $72.00 to $75.00
2015-10-25 Reiterated Rating Canaccord Genuity Buy $72.00
2015-10-23 Reiterated Rating William Blair Hold
2015-10-23 Lower Price Target Goldman Sachs Neutral $76.00 to $70.00
2015-10-23 Lower Price Target Barclays Equal Weight $78.00 to $72.00
2015-10-23 Lower Price Target RBC Capital Sector Perform $77.00 to $70.00
2015-10-22 Lower Price Target Mizuho Neutral $76.00 to $68.00
2015-10-16 Upgrade Wells Fargo Underperform to Market Perform
2015-10-16 Upgrade Wells Fargo & Co. Underperform to Market Perform
2015-08-03 Lower Price Target Canaccord Genuity Buy $85.00 to $82.00
2015-06-23 Downgrade Goldman Sachs Buy to Neutral $76.00
2015-06-16 Initiated Coverage KeyBanc Sector Weight
2015-06-09 Reiterated Rating Jefferies Group Hold
2015-06-01 Reiterated Rating Mizuho Buy $71.00 to $76.00
2015-05-24 Reiterated Rating Canaccord Genuity Buy $85.00
2015-04-23 Set Price Target Canaccord Genuity Buy $85.00
2015-04-14 Boost Price Target Canaccord Genuity Buy $82.00 to $85.00
2015-03-27 Initiated Coverage JMP Securities Market Perform
2015-03-25 Downgrade Deutsche Bank Buy to Hold $77.00 to $80.00
2015-03-25 Downgrade Deutsche Bank AG Buy to Hold $77.00 to $80.00
2015-03-03 Upgrade Canaccord Genuity Hold to Buy $63.00 to $82.00
2015-03-02 Initiated Coverage Barclays Equal Weight $78.00
2015-02-26 Downgrade Goldman Sachs Conviction-Buy to Buy
2015-02-23 Downgrade Bank of America Neutral to Underperform $71.00 to $68.00
2015-02-23 Downgrade Bank of America Corp. Neutral to Underperform $71.00 to $68.00
2015-01-30 Boost Price Target Jefferies Group Hold $65.00 to $74.00
2015-01-30 Boost Price Target Citigroup Inc. Neutral $65.00 to $74.00
2015-01-30 Downgrade Wells Fargo & Co. Market Perform to Underperform
2015-01-30 Boost Price Target Mizuho Neutral $64.00 to $71.00
2015-01-30 Downgrade Wells Fargo Market Perform to Underperform
2015-01-29 Downgrade Craig Hallum Buy to Hold
2015-01-28 Set Price Target Morgan Stanley Sell $69.00
2015-01-02 Upgrade Raymond James Underperform to Market Perform
2015-01-02 Upgrade Raymond James Financial Inc. Underperform to Market Perform
2014-12-29 Set Price Target Bank of America Hold $65.00 to $68.00
2014-12-18 Reiterated Rating Goldman Sachs Buy $79.00
2014-11-13 Upgrade Deutsche Bank Hold to Buy $64 to $75
2014-09-03 Upgrade Goldman Sachs Buy to Conviction-Buy $66.00 to $78.00
2014-07-25 Boost Price Target Maxim Group Buy $68.00 to $74.00
2014-07-25 Reiterated Rating Citigroup Inc. Neutral $60.00 to $65.00
2014-07-25 Boost Price Target Canaccord Genuity Hold $55.00 to $58.00
2014-07-24 Reiterated Rating Mizuho Neutral
2014-07-03 Boost Price Target Mizuho Neutral $63.00 to $64.00
2014-05-08 Upgrade Bank of America Underperform to Neutral $58.00
2014-04-14 Boost Price Target Credit Suisse $55.00 to $62.00
2014-04-11 Boost Price Target Goldman Sachs $61.00 to $67.00
2014-04-02 Boost Price Target Mizuho Neutral $54.00 to $63.00
2014-03-19 Boost Price Target RBC Capital $52.00 to $53.00
2014-03-10 Boost Price Target Goldman Sachs $61.00
2014-03-10 Initiated Coverage Piper Jaffray Neutral
2014-01-31 Lower Price Target SunTrust $66.00 to $60.00
2014-01-31 Lower Price Target Deutsche Bank $62.00 to $59.00
2014-01-31 Lower Price Target Mizuho Neutral $64.00 to $54.00
2014-01-28 Initiated Coverage Maxim Group Buy $73.00 to $68.00
2014-01-27 Lower Price Target FBR & Co. Market Perform $68.00 to $60.00
2013-12-18 Initiated Coverage JMP Securities Market Perform
2013-12-12 Reiterated Rating Morgan Stanley Underweight $58.00
2013-12-11 Reiterated Rating Citigroup Inc. Neutral $59.00 to $58.00
2013-12-10 Downgrade Bank of America Buy to Underperform $64.00 to $55.00
2013-11-19 Initiated ISI Group Neutral $63
2013-11-19 Initiated Coverage Evercore ISI Neutral $63.00
2013-11-08 Initiated Coverage FBR & Co. Market Perform $68.00
2013-10-18 Lower Price Target Canaccord Genuity Hold $59.00 to $55.00
2013-10-17 Lower Price Target Mizuho Neutral $62.00 to $58.00
2013-10-11 Reiterated Rating Citigroup Inc. Neutral $64.00 to $60.00
2013-10-10 Reiterated Rating Wells Fargo & Co. Market Perform
2013-10-10 Reiterated Rating Wells Fargo Market Perform
2013-10-02 Boost Price Target Goldman Sachs Buy $66.00 to $71.00
2013-09-19 Initiated Coverage Craig Hallum Buy
2013-07-12 Initiated Robert W. Baird Neutral $58
2013-01-29 Initiated Oppenheimer Underperform $53
2013-01-24 Reiterated Mizuho Neutral $63 to $58
2012-07-02 Reiterated Mizuho Neutral $61 to $62
2012-06-21 Initiated Canaccord Genuity Hold $60
2011-11-07 Upgrade RBC Capital Mkts Sector Perform to Outperform $50 to $68
2011-10-25 Downgrade Standpoint Research Buy to Hold
2011-10-10 Downgrade Maxim Group Buy to Hold
2011-08-11 Upgrade Standpoint Research Hold to Buy $60
2016-06-24 Downgrade Jyske Bank Neutral to Sell
2016-06-07 Reiterated Rating Morgan Stanley Sell
2016-06-03 Reiterated Rating Mizuho Buy $84.00
2016-05-24 Reiterated Rating Credit Suisse Hold
2016-05-24 Reiterated Rating Credit Suisse Group AG Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
RUSCKOWSKI STEPHEN H President and CEO 0.13%  (191069) COV / DGX / XRX /
HAGEMANN ROBERT SVP & Chief Financial Officer 0.09%  (126722) DGX / GPK / R / ZMH /
Doherty Catherine T. SVP, Clinical Franchises 0.05%  (67941) DGX /
GUINAN MARK Senior Vice President & CFO 0.04%  (53767) DGX / HRC /
Cunningham Everett SVP, Commercial 0.03%  (45916) DGX /
PREVOZNIK MICHAEL E SVP & General Counsel 0.03%  (39771) DGX /
Davis J. E. SVP, Operations 0.03%  (37067) DGX /
STANZIONE DANIEL 0.02%  (34675) DGX / INAP /
Cohen Jon R SVP and Chief Medical Officer 0.02%  (31757) DGX /
BUEHLER WILLIAM F 0.02%  (26225) DGX /
WILENSKY GAIL R 0.02%  (24960) DGX / UNH /
BRITELL JENNE K 0.01%  (21476) CCK / DGX / URI /
EGLINTON MANNER CARRIE SVP, Advanced Diagnostics 0.01%  (21274) DGX /
Haydon John B. SVP, Operations 0.01%  (19890) DGX /
ZIEGLER JOHN B 0.01%  (16557) DGX /
PFEIFFER GARY M 0.01%  (15534) DGX / INAP / SZYM /
MAIN TIMOTHY L 0.01%  (14691) DGX / JBL /
RING TIMOTHY M 0.01%  (14585) BCR / BDX / DGX /
BALDWIN JOHN C MD 0.01%  (12949) DGX /
BONGIORNO THOMAS F VP and Corporate Controller 0.01%  (11837) DGX / EVHC /
ORDONEZ KATHY SVP, Diagnostic Solutions 0.01%  (9569) DGX / PACB /
Gregg Vicky B 0.01%  (8525) ACHC / DGX / FHN / TMH /

Comments